slots game pc
Will the Trump administration raise tariffs on car parts and vehicles?Assessing the EU’s new migration pactGriezmann double makes it nine wins in a row for Atletico after stunning 4-3 victory over Sevilla
Report: UCF HC Gus Malzahn to become Florida State OC
ST Picks: ‘We cried together’ — Healthcare staff share stories in new book
Why Domo (DOMO) Stock Is Trading Lower Today
CoreCivic, Inc. (NYSE:CXW) Shares Acquired by Algert Global LLC
Published 4:27 pm Saturday, November 30, 2024 By Data Skrive Foster Moreau was a limited participant in his most recent practice. The New Orleans Saints take on the Los Angeles Rams at 4:05 PM ET on Sunday in Week 13. Take a look at Moreau’s stats on this page. Entering Week 13, Moreau has 15 receptions for 217 yards — 14.5 yards per catch — and three receiving touchdowns. Digging deeper into his season stats, he has been targeted on 21 occasions. Don’t miss a touchdown this NFL season. Catch every score with NFL RedZone on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Start your risk free trial today and watch seven hours of commercial-free football from every NFL game every Sunday. BetMGM is one of the most trusted Sportsbooks in the nation. Start with as little as $1 and place your bets today . Catch NFL action all season long on Fubo. Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .
Gus Malzahn is leaving his post as UCF's head coach to reunite with Florida State coach Mike Norvell as the Seminoles' offensive coordinator, ESPN reported on Saturday. Norvell, who served as a graduate assistant under Malzahn at Tulsa in 2007-08, relinquished his role as FSU's primary playcaller amid a staff shakeup this season. Florida State, 1-7 in the Athletic Coast Conference this season, entered Saturday's season finale against Florida at 2-9 and ranked No. 131 in the nation in total offense. UCF also endured a tough 2024 season, going 4-8 after losing eight of its last nine games. During Malzahn's four-year tenure, the Knights went 28-24, including 5-13 in the Big 12 Conference the last two seasons. Malzahn, 59, is 105-62 in 13 seasons as a college head coach, highlighted by a 68-35 mark in eight seasons at Auburn -- which included a BCS title game appearance in 2013. He served as offensive coordinator and playcaller when the Tigers won the national title in 2010. Malzahn will be tasked with revitalizing a Florida State offense that helped produce a 13-1 campaign in 2023, when the Seminoles were denied a spot in the College Football Playoff. Over the last three seasons at UCF, his rushing attack has been in the Top 10 in the nation. In his 19 seasons as a college head coach or offensive coordinator, Malzahn's teams have averaged 447.7 yards per game, and three of his teams eclipsed 7,000 yards in a season. --Field Level MediaMedirex Systems Inc. joins the Vector Institute's FastLane program to accelerate AI-fueled growthMoore scores 20 as Norfolk State beats Grambling 76-70
Welcome to OncLive On Air ® ! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive ® , which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, supported by BeiGene, we had the pleasure of speaking with Mazyar Shadman, MD, MPH, about updates in zanubrutinib (Brukinsa)–focused research in chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Shadman is an associate professor in the Clinical Research Division and the medical director of Cellular Immunotherapy at the Fred Hutchinson Cancer Center in Seattle, Washington. In our exclusive interview, Dr Shadman discussed key findings and implications from several clinical trials investigating zanubrutinib as monotherapy and in combination with agents such as obinutuzumab (Gazyva), sonrotoclax (BGB-11417), and venetoclax (Venclexta) in patients with CLL and other B-cell malignancies. ___ That’s all we have for today! Thank you for listening to this episode of OncLive On Air , supported by BeiGene. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today’s episode of OncLive On Air , please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air . *OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
